| 产品详情 |
| Edit |   |
|---|
| Product Name | Lazabemide |
|---|
| Description | Purity >98%. Monoamine oxidases, MAO-A and MAO-B, regulate the intracellular concentrations of biogenic monoamines such as 5-hydroxytryptamine and dopamine via oxidative deamination. Inhibitors of MAO-A are widely used for the therapy of affective disorders, whereas MAO-B inhibitors have clinical efficacy in the treatment of Parkinson's disease. Lazabemide is a reversible inhibitor of monoamine oxidase B (MAO-B) with IC50 values of 0.48 and 1.5 µM measured in platelets of human subjects ages 19-36 and 60-78, respectively. It is structurally similar to the MAO-B preferential substrate phenylethylamine and can be oxidized by MAO-B, forming tightly, but reversibly, bound adducts with the active site of the enzyme. The selectivity of lazabemide for MAO-B inhibition has been demonstrated in both in vitro and ex vivo conditions and it was evaluated in clinical trials for possible neuroprotective actions in the treatment of Parkinson's disease. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | N-(2-aminoethyl)-5-chloro-2-pyridinecarboxamide, Ro 19-6327/000 |
|---|
| Gene, Accession, CAS # | CAS: 103878-84-8 |
|---|
| Catalog # | LS-H8425 |
|---|
| Price | |
|---|
| Order / More Info | Lazabemide from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|